Remsima SC 120 mg – a new generation of biosimilar drugs
Milan Lukáš1
+ Affiliation
To read this article in full, please register for free on this website.
Benefits for subscribers
Benefits for logged users
Literature
1. Remsima; summary of product characteristics. 2021 [online]. Available from: https: //www.ema.europa.eu/en/documents/product-information/remsima-epar-product-information_en.pdf.
2. Schreiber S, D’Haens G, Cummings F et al. Switching from intravenous to subcutaneous infliximab in patients with active inflammatory bowel disease. Post hoc analysis of pre-post switch outcomes from multicentre, randomized, controlled pivotal trial. UEGW 2021, P0472.
3. Lukáš M. První generace biologických léčiv anti-TNF alfa monoklonální protilátky. In: Pokroky v diagnostice a léčbě idiopatických střevních zánětů. Praha: Galén 2019.
4. Kennedy NA, Heap GA, Green HD et al. Predictors of anti-TNF therapy failure in anti-TNF naive patients with active luminal Crohn’s disease. A prospective multicentre cohort study. Lancet Gastroenterol Hepatol 2019; 4(5): 341–353. doi: 10.1016/S2468-1253(19)30012-3.